Halozyme Story

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;'>HT</div>
HALO -- USA Stock  

USD 26.59  1.15  4.15%

Filed transaction by Halozyme Therapeutics Inc director. Unconventional Insider trading
Published over a year ago
View all stories for Halozyme Therapeutics | View All Stories
Halozyme Therapeutics exotic insider transaction detected
Transaction by Randal Kirk

How important is Halozyme Therapeutics's Liquidity

Halozyme Therapeutics financial leverage refers to using borrowed capital as a funding source to finance Halozyme Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Halozyme Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Halozyme Therapeutics's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions. It is good to see analyst projects for Halozyme Therapeutics, but it might be worth checking our own buy vs. sell analysis

Bona fide gift to Connie Matsui of 8000 shares of Halozyme Therapeutics subject to Section 16

Legal trades by Halozyme Therapeutics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Halozyme insider trading alert for gift of common stock by Connie Matsui, the corporate stakeholder, on 14th of September 2020. This event was filed by Halozyme Therapeutics Inc with SEC on 2020-09-14. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down Halozyme Therapeutics Indicators

Halozyme Therapeutics insider trading alert for general transaction of common stock by Randal Kirk, the corporate stakeholder, on September 1, 2019. This event was filed by Halozyme Therapeutics Inc with SEC on 2009-05-08. Statement of changes in beneficial ownership - SEC Form 4